Clinical implications of the intrinsic molecular subtypes of breast cancer

La Vecchia, 2010, Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975, Ann Oncol, 21, 1323, 10.1093/annonc/mdp530

Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093

Prat, 2011, Deconstructing the molecular portraits of breast cancer, Mol Oncol, 5, 5, 10.1016/j.molonc.2010.11.003

Prat, 2012, PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer, Breast Cancer Res Treat, 135, 301, 10.1007/s10549-012-2143-0

Prat, 2010, Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Res, 12, R68, 10.1186/bcr2635

Cancer Genome Atlas, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412

Parker, 2009, Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, 27, 1160, 10.1200/JCO.2008.18.1370

Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303

Maisonneuve, 2014, Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes, Breast Cancer Res, 16, R65, 10.1186/bcr3679

Prat, 2013, Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer, J Clin Oncol, 31, 203, 10.1200/JCO.2012.43.4134

Cheang, 2009, Ki67 Index, HER2 status, and prognosis of patients with luminal B breast Cancer, J Natl Cancer Inst, 101, 736, 10.1093/jnci/djp082

Prat, 2014, Predicting response and survival in chemotherapy-treated triple-negative breast cancer, Br J Cancer, 111, 1532, 10.1038/bjc.2014.444

Sikov, 2014, Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT)+/− carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance), San Ant Breast Cancer Symp, 2012, S4

Bastien, 2012, PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers, BMC Med Genomics, 5, 44, 10.1186/1755-8794-5-44

Prat, 2013, Molecular characterization of basal-like and non-basal-like triple-negative breast cancer, Oncologist, 18, 123, 10.1634/theoncologist.2012-0397

Dunbier, 2011, Association between breast cancer subtypes and response to neoadjuvant anastrozole, Steroids, 76, 736, 10.1016/j.steroids.2011.02.025

Chia, 2012, A 50-Gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen, Clin Cancer Res, 18, 4465, 10.1158/1078-0432.CCR-12-0286

Ellis, 2011, J Clin Oncol, 29, 2342, 10.1200/JCO.2010.31.6950

Dowsett, 2013, Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J Clin Oncol, 31, 2783, 10.1200/JCO.2012.46.1558

Gnant, 2014, Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone, Ann Oncol, 25, 339, 10.1093/annonc/mdt494

Martín, 2014, Prospective study of the impact of the Prosigna™ assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: a GEICAM study, San Ant Breast Cancer Symp, 2012

Nielsen, 2010, A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer, Clin Cancer Res, 16, 5222, 10.1158/1078-0432.CCR-10-1282

Prat, 2014, Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer, J Natl Cancer Inst, 106, 10.1093/jnci/dju152

Curtis, 2012, The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups, Nature, 486, 346, 10.1038/nature10983

Prat, 2014, Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study, Clin Cancer Res, 20, 511, 10.1158/1078-0432.CCR-13-0239

Carey, 2013, Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer, Proc Am Soc Clin Oncol, a500

Prat, 2012, Practical implications of gene-expression-based assays for breast oncologists, Nat Rev Clin Oncol, 9, 48, 10.1038/nrclinonc.2011.178

Dowsett, 2011, Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in Breast Cancer Working Group, J Natl Cancer Inst, 103, 1656, 10.1093/jnci/djr393

Hammond, 2010, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol, 28, 2784, 10.1200/JCO.2009.25.6529

Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984

McCullough, 2014, Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study, Breast Cancer Res Treat, 143, 485, 10.1007/s10549-013-2827-0

Prat, 2013, Prognostic significance of progesterone receptor–positive tumor cells within immunohistochemically defined luminal A breast cancer, J Clin Oncol, 31, 203, 10.1200/JCO.2012.43.4134

Roberts, 2013, An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers, Nat Genet, 45, 970, 10.1038/ng.2702

Kuong, 2013, APOBEC3B mutagenesis in cancer, Nat Genet, 45, 964, 10.1038/ng.2736

Prat, 2014, Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status, Breast Cancer Res Treat, 147, 185, 10.1007/s10549-014-3056-x

Foulkes, 2003, Germline BRCA1 mutations and a basal epithelial phenotype in breast Cancer, J Natl Cancer Inst, 95, 1482, 10.1093/jnci/djg050

Schneider, 2008, Triple-negative breast cancer: risk factors to potential targets, Clin Cancer Res, 14, 8010, 10.1158/1078-0432.CCR-08-1208

Prat, 2013, Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity, Sci Rep, 3, 3544, 10.1038/srep03544

Hoadley, 2014, Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin, Cell, 158, 929, 10.1016/j.cell.2014.06.049

Lim, 2009, Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers, Nat Med, 15, 907, 10.1038/nm.2000

Molyneux, 2010, BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells, Cell Stem Cell, 7, 403, 10.1016/j.stem.2010.07.010

Keller, 2012, Defining the cellular precursors to human breast cancer, Proc Natl Acad Sci, 109, 2772, 10.1073/pnas.1017626108

Anderson, 2014, How many etiological subtypes of breast cancer: two, three, four, or more?, J Natl Cancer Inst, 106, 10.1093/jnci/dju165

Millikan, 2008, Epidemiology of basal-like breast cancer, Breast Cancer Res Treat, 109, 123, 10.1007/s10549-007-9632-6

Liu, 2012, PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy, San Ant Breast Cancer Symp, 2012

Martín, 2013, PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer, Breast Cancer Res Treat, 138, 457, 10.1007/s10549-013-2416-2

Cheang, 2012, Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial, Clin Cancer Res, 18, 2402, 10.1158/1078-0432.CCR-11-2956

Filipits, 2014, The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer, Clin Cancer Res, 20, 1298, 10.1158/1078-0432.CCR-13-1845

Sestak, 2015, J Clin Oncol, 33, 916, 10.1200/JCO.2014.55.6894

Sestak, 2013, Factors predicting late recurrence for estrogen receptor–positive breast cancer, J Natl Cancer Inst, 105, 1504, 10.1093/jnci/djt244

Usary, 2013, Predicting drug responsiveness in human cancers using genetically engineered mice, Clin Cancer Res, 19, 4889, 10.1158/1078-0432.CCR-13-0522

von Minckwitz, 2013, Response-guided neoadjuvant chemotherapy for breast cancer, J Clin Oncol, 31, 3623, 10.1200/JCO.2012.45.0940

von Minckwitz, 2012, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol, 30, 1796, 10.1200/JCO.2011.38.8595

Carey, 2007, The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin Cancer Res, 13, 2329, 10.1158/1078-0432.CCR-06-1109

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172.

Paik, 2006, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, 24, 3726, 10.1200/JCO.2005.04.7985

Albain, 2010, Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, 11, 55, 10.1016/S1470-2045(09)70314-6

2012, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Lancet, 379, 432, 10.1016/S0140-6736(11)61625-5

Coates, 2012, Is adjuvant chemotherapy useful for women with luminal A breast cancer?, J Clin Oncol, 30, 1260, 10.1200/JCO.2011.37.7879

Hayes, 2012, Targeting adjuvant chemotherapy: a good idea that needs to be proven!, J Clin Oncol, 30, 1264, 10.1200/JCO.2011.38.4529

Mackey, 2013, Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial, Lancet Oncol, 14, 72, 10.1016/S1470-2045(12)70525-9

Ellis, 2008, Outcome prediction for estrogen receptor–positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics, J Natl Cancer Inst, 100, 1380, 10.1093/jnci/djn309

Hugh, 2009, Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial, J Clin Oncol, 27, 1168, 10.1200/JCO.2008.18.1024

Iwamoto, 2012, Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry, J Clin Oncol, 30, 729, 10.1200/JCO.2011.36.2574

Cheang, 2012, Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABCG, Proc Am Soc Clin Oncol, a1008

Prat, 2012, Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen, Ann Oncol, 23, 2866, 10.1093/annonc/mds080

Vaz-Luis, 2012, Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study, Breast Cancer Res, 14, R129, 10.1186/bcr3324

Perez, 2011, Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31, J Clin Oncol, 29, 3366, 10.1200/JCO.2011.35.0868

de Azambuja, 2014, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response, Lancet Oncol, 15, 1137, 10.1016/S1470-2045(14)70320-1

Piccart-Gebhart, 2014, Proc Am Soc Clin Oncol, LBA4

Tolaney, 2015, Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer, N Engl J Med, 372, 134, 10.1056/NEJMoa1406281

Eiermann W, Baselga J, Semiglazov V, Byakhov M, Ciruelos E, Ojeda B, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384.

Buzdar, 2005, Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer, J Clin Oncol, 23, 3676, 10.1200/JCO.2005.07.032

Eiermann, 2008, Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

Gianni, 2014, Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort, Lancet Oncol, 15, 640, 10.1016/S1470-2045(14)70080-4

Untch, 2008, Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial, Ann Oncol, 19, 1090, 10.1093/annonc/mdn005

Perez, 2014, Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831, J Clin Oncol, 32, 3744, 10.1200/JCO.2014.55.5730

Pogue-Geile, 2015, Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial, J Clin Oncol, 33, 1340, 10.1200/JCO.2014.56.2439

Gianni, 2012, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 25, 10.1016/S1470-2045(11)70336-9

Rimawi, 2013, Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006, J Clin Oncol, 31, 1726, 10.1200/JCO.2012.44.8027

Prat, 2013, Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy, J Clin Oncol, 31, 1703, 10.1200/JCO.2012.48.4998

Rimawi, 2014, TBCRC023: a randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer, San Ant Breast Cancer Symp, 2012

Lehmann, 2011, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, 121, 2750, 10.1172/JCI45014

Lehmann, 2014, Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes, J Pathol, 232, 142, 10.1002/path.4280

Burstein, 2015, Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer, Clin Cancer Res, 21, 1688, 10.1158/1078-0432.CCR-14-0432

Masuda, 2013, Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes, Clin Cancer Res, 19, 5533, 10.1158/1078-0432.CCR-13-0799

Loi, 2014, Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Ann Oncol, 25, 1544, 10.1093/annonc/mdu112

Ali, 2014, Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients, Ann Oncol, 25, 1536, 10.1093/annonc/mdu191

Liedtke, 2008, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, 26, 1275, 10.1200/JCO.2007.14.4147

Sikov, 2014, J Clin Oncol

von Minckwitz, 2014, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial, Lancet Oncol, 15, 747, 10.1016/S1470-2045(14)70160-3

Tutt, 2014, The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012), San Ant Breast Cancer Symp, 2012

Gucalp, 2013, Phase II trial of bicalutamide in patients with androgen receptor–positive, estrogen receptor–negative metastatic breast cancer, Clin Cancer Res, 19, 5505, 10.1158/1078-0432.CCR-12-3327